MX391157B - Terapia basada en proteina y diagnostico de patologia mediada por tau en la enfermedad de alzheimer. - Google Patents

Terapia basada en proteina y diagnostico de patologia mediada por tau en la enfermedad de alzheimer.

Info

Publication number
MX391157B
MX391157B MX2017005573A MX2017005573A MX391157B MX 391157 B MX391157 B MX 391157B MX 2017005573 A MX2017005573 A MX 2017005573A MX 2017005573 A MX2017005573 A MX 2017005573A MX 391157 B MX391157 B MX 391157B
Authority
MX
Mexico
Prior art keywords
tau
alzheimer
disease
protein
antibodies
Prior art date
Application number
MX2017005573A
Other languages
English (en)
Spanish (es)
Inventor
Branislav Kovácech
Eva Kontseková
Michal Noväk
Norbert Zilka
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47216372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX391157(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of MX391157B publication Critical patent/MX391157B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
MX2017005573A 2011-09-19 2012-09-14 Terapia basada en proteina y diagnostico de patologia mediada por tau en la enfermedad de alzheimer. MX391157B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536339P 2011-09-19 2011-09-19
US201261653115P 2012-05-30 2012-05-30
PCT/IB2012/002246 WO2013041962A1 (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

Publications (1)

Publication Number Publication Date
MX391157B true MX391157B (es) 2025-03-21

Family

ID=47216372

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005573A MX391157B (es) 2011-09-19 2012-09-14 Terapia basada en proteina y diagnostico de patologia mediada por tau en la enfermedad de alzheimer.
MX2014003357A MX347505B (es) 2011-09-19 2012-09-14 Terapia basada en proteína y diagnóstico de patalogía mediada por tau en la enfermedad de alzheimer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014003357A MX347505B (es) 2011-09-19 2012-09-14 Terapia basada en proteína y diagnóstico de patalogía mediada por tau en la enfermedad de alzheimer.

Country Status (30)

Country Link
US (5) US9518101B2 (enExample)
EP (2) EP3275461A1 (enExample)
JP (7) JP6253583B2 (enExample)
KR (3) KR20210099167A (enExample)
CN (3) CN109265543B (enExample)
AU (3) AU2012311234B2 (enExample)
BR (1) BR112014006376B1 (enExample)
CA (1) CA2848346A1 (enExample)
CL (3) CL2014000679A1 (enExample)
CY (1) CY1119792T1 (enExample)
DK (1) DK2758433T3 (enExample)
ES (1) ES2656442T3 (enExample)
HR (1) HRP20180083T8 (enExample)
HU (1) HUE036177T2 (enExample)
IL (4) IL231201B (enExample)
LT (1) LT2758433T (enExample)
ME (1) ME03008B (enExample)
MX (2) MX391157B (enExample)
MY (1) MY183989A (enExample)
PL (1) PL2758433T3 (enExample)
PT (1) PT2758433T (enExample)
RS (1) RS56852B1 (enExample)
RU (2) RU2018102103A (enExample)
SG (4) SG10201912955PA (enExample)
SI (1) SI2758433T1 (enExample)
SM (1) SMT201800109T1 (enExample)
TR (1) TR201800669T4 (enExample)
UA (2) UA115657C2 (enExample)
WO (1) WO2013041962A1 (enExample)
ZA (1) ZA201401333B (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244174A1 (en) * 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
KR20150036346A (ko) 2012-07-03 2015-04-07 워싱턴 유니버시티 Tau에 대한 항체
RS60080B1 (sr) 2012-08-16 2020-05-29 Ipierian Inc Metodi lečenja tauopatije
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
EP3074420A2 (en) * 2013-11-27 2016-10-05 Ipierian, Inc. Methods of treating a tauopathy
WO2015098963A1 (ja) * 2013-12-26 2015-07-02 東亞合成株式会社 カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
EA035530B1 (ru) * 2014-06-26 2020-06-30 Янссен Вэксинс Энд Превеншн Б.В. Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
IL284949B2 (en) 2014-11-14 2024-06-01 Voyager Therapeutics Inc Modulatory polynucleotides
DK3221349T3 (da) 2014-11-19 2021-01-04 Axon Neuroscience Se Humaniserede tau-antistoffer i Alzheimers sygdom
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
KR20250027278A (ko) 2015-07-06 2025-02-25 유씨비 바이오파마 에스알엘 타우 결합 항체
KR102742965B1 (ko) 2015-07-06 2024-12-13 유씨비 바이오파마 에스알엘 타우 결합 항체
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201518675D0 (en) * 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109415434B (zh) * 2016-05-02 2022-12-30 普罗塞纳生物科学有限公司 识别tau的抗体
MX2018013384A (es) * 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
KR102506091B1 (ko) * 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
EP3458588B1 (en) 2016-05-18 2025-10-29 Voyager Therapeutics, Inc. Modulatory polynucleotides
KR101997319B1 (ko) * 2016-06-21 2019-07-08 전남대학교산학협력단 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
FR3058143B1 (fr) 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CR20190271A (es) 2016-12-07 2019-09-03 Genentech Inc Anticuerpos antitau y métodos de uso
AU2017373884B2 (en) 2016-12-07 2024-11-14 Ac Immune Sa Anti-tau antibodies and methods of their use
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11001615B2 (en) 2016-12-21 2021-05-11 Adel Inc. Mutated tau protein fragment and use thereof
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
WO2018178077A1 (en) * 2017-03-28 2018-10-04 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
US20210147481A1 (en) * 2017-04-21 2021-05-20 Ohio University Peptide-based inhibitors of mark family proteins
WO2018204546A2 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
JP7160929B2 (ja) 2017-10-02 2022-10-25 ブラックソーン セラピューティクス インコーポレイテッド 神経画像処理及び遺伝子発現マッピングデータのコンピュータ生成型予測応用のための方法及びシステム
MA50397A (fr) 2017-10-16 2020-08-26 Eisai R&D Man Co Ltd Anticorps anti-tau et leurs utilisations
AU2018355325B2 (en) 2017-10-25 2024-11-28 Ac Immune S.A. Compositions of phosphorylated tau peptides and uses thereof
US11773148B2 (en) * 2017-10-27 2023-10-03 United Neuroscience Tau peptide immunogen constructs
US20200339670A1 (en) * 2017-12-20 2020-10-29 Michael Heneka Novel means and methods for treating neurodegenerative diseases
WO2019175735A1 (en) 2018-03-11 2019-09-19 Koorosh Shahpasand Conformation-independent antibodies against neurotoxic tau proteins
AU2019244481A1 (en) * 2018-03-28 2020-10-01 Axon Neuroscience Se Antibody-based methods of detecting and treating Alzheimer's disease
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
RU2679059C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
EP3788062A4 (en) * 2018-05-03 2022-02-16 Washington University Methods of diagnosing and treating based on site-specific tau phosphorylation
CA3247235A1 (en) 2018-07-03 2025-11-29 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression
WO2020028141A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination therapy
PE20211777A1 (es) * 2018-11-08 2021-09-08 Prothena Biosciences Ltd Anticuerpos que reconocen tau
EP3883602A4 (en) * 2018-11-19 2023-04-12 The Board Of Regents Of The University Of Texas System TAU PEPTIDE ANTIGENS AND ANTIBODIES BINDING TO THEM FOR THE TREATMENT OF TAUOPATHIES
EP3894438A1 (en) * 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
US11684576B2 (en) 2019-02-08 2023-06-27 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021009440A (es) * 2019-02-08 2021-09-10 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CN113631573B (zh) * 2019-03-25 2024-06-04 国家医疗保健研究所 抗Tau抗体及其在制备用于治疗疾病的药物中的用途
JP7617852B2 (ja) * 2019-04-24 2025-01-20 ヤンセン ファーマシューティカルズ，インコーポレーテッド タウワクチンの異種投与
EP3977135A1 (en) * 2019-05-31 2022-04-06 Eli Lilly And Company Compounds and methods targeting human tau
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
AU2020325770B2 (en) * 2019-08-06 2022-08-25 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
JP7780200B2 (ja) * 2019-08-13 2025-12-04 ワシントン・ユニバーシティ Ｍｔｂｒタウアイソフォームを検出する方法およびその使用
CN114531877B (zh) * 2019-08-15 2024-11-15 学校法人东京医科大学 不受clsp阻碍物质影响的clsp衍生物和clsp活性的增强/保护剂
EP4028040A2 (en) * 2019-09-09 2022-07-20 Axon Neuroscience SE Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
WO2021050733A1 (en) 2019-09-10 2021-03-18 Washington University Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
JOP20220092A1 (ar) * 2019-10-22 2023-01-30 Biogen Ma Inc جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
IL270800A (en) * 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
CN110841059A (zh) * 2019-12-03 2020-02-28 南通大学 老年性痴呆小鼠模型的制备方法
AU2021217290A1 (en) * 2020-02-05 2022-07-21 Sumitomo Pharma Co., Ltd. Determination agent and determination method for tauopathy and dementia-related diseases
IL298215A (en) * 2020-05-19 2023-01-01 Othair Prothena Ltd A multi-epitope vaccine for the treatment of Alzheimer's disease
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
KR20230080398A (ko) * 2020-08-07 2023-06-07 프로테나 바이오사이언시즈 리미티드 알츠하이머 질환 치료용 tau 백신
IL300347A (en) * 2020-08-07 2023-04-01 Othair Prothena Ltd Multi-shot vaccine for the treatment of Alzheimer's disease
CA3203308A1 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
WO2022133324A1 (en) * 2020-12-18 2022-06-23 Sangamo Therapeutics, Inc. Improved pharmaceutical compositions containing adeno-associated viral vector
WO2022174026A1 (en) * 2021-02-14 2022-08-18 Prothena Biosciences Limited Methods of using antibodies recognizing tau
JP2024509683A (ja) * 2021-02-19 2024-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｐｔ２１７ ｔａｕ抗体
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
CN113430230A (zh) * 2021-06-24 2021-09-24 南通大学 tau截断体蛋白在诱导tau病理聚集中的应用
WO2023060278A2 (en) * 2021-10-08 2023-04-13 Tiberias Technology (Hk) Limited Tibtech methods and compositions for detecting cdh17
CN113861441A (zh) * 2021-10-28 2021-12-31 南开大学 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
US20250186595A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
EP4587470A1 (en) 2022-09-15 2025-07-23 Voyager Therapeutics, Inc. Tau binding compounds
WO2025019332A1 (en) * 2023-07-14 2025-01-23 Alzpath, Inc. Methods for remote blood collection, extraction and analysis of neuro biomarkers
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations
CN117624354B (zh) * 2023-11-30 2024-07-12 无锡傲锐东源生物科技有限公司 一种抗人乙酰化tau281兔单克隆抗体及其应用
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993011231A1 (en) * 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
WO1995005853A1 (en) 1993-08-26 1995-03-02 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
EP0791067B1 (en) * 1994-10-28 2008-12-17 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Protein kinase npk-110
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
JP3830525B2 (ja) 1995-11-10 2006-10-04 サイトジェン，コーポレーション 組織横断輸送を強化するペプチドとその同定法および使用法
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
JP3383618B2 (ja) 1999-08-18 2003-03-04 松下電器産業株式会社 移動体通信端末装置及び受信強度検出方法
WO2001018544A1 (en) * 1999-09-09 2001-03-15 Mcgill University Diagnosis, prognosis and treatment of trinucleotide repeat-associated diseases and intranuclear inclusions-associated diseases
ATE326700T1 (de) 1999-09-09 2006-06-15 Max Planck Gesellschaft SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
ES2276732T3 (es) 2001-09-03 2007-07-01 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Mimotopos de antigenos y vacuna contra enfermedades cancerosas.
TWI226905B (en) 2001-10-19 2005-01-21 Bioware Technology Co Ltd Low pressure-accelerated particle gene gun
DK1521831T3 (da) * 2002-07-12 2008-06-30 Axon Neuroscience Transgent dyr der udtrykker trunkeret alzheimers tauprotein
JP2006513259A (ja) * 2002-07-24 2006-04-20 イノジェネティックス・ナムローゼ・フェンノートシャップ ベータ−アミロイド生成および／または凝集に関連した疾病の防止、処置および診断
US7521230B2 (en) * 2002-10-16 2009-04-21 Board Of Regents Of The University Of Nebraska Nucleic acid encoding a Brain Derived Tau Kinase polypeptide and methods of use thereof
EP1516930A1 (en) 2003-09-16 2005-03-23 Georg-August Universität Göttingen Cellular model of tauopathies for lead identification and drug discovery
KR20070007253A (ko) 2003-10-08 2007-01-15 이바이오사이언스 천연 면역글로불린 결합 물질 및 이의 제조 방법 및 사용방법
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2008084483A1 (en) * 2007-01-11 2008-07-17 Ramot At Tel Aviv University Ltd. Novel therapeutics based on tau/microtubule dynamics
EP2149584B1 (en) * 2007-04-20 2017-12-13 The Chemo-Sero-Therapeutic Research Institute Method for enhancing immune response with peptide
US20110212075A1 (en) * 2007-06-25 2011-09-01 Siemens Aktiengesellschaft Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP3329932A1 (en) 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
EP2470211B1 (en) * 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
KR20120101053A (ko) 2009-11-06 2012-09-12 더 제이. 데이비드 글래드스톤 인스티튜트 타우 레벨을 조절하기 위한 방법 및 조성물
WO2011061625A2 (en) * 2009-11-19 2011-05-26 Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
CL2010000019A1 (es) * 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
JP6499345B2 (ja) 2019-04-10
JP6950981B2 (ja) 2021-10-20
US9518101B2 (en) 2016-12-13
JP2017042172A (ja) 2017-03-02
JP6637124B2 (ja) 2020-01-29
CN115417916A (zh) 2022-12-02
JP6360869B2 (ja) 2018-07-18
CL2016000215A1 (es) 2017-08-18
CN109265543B (zh) 2022-04-26
IL259775B (en) 2020-05-31
JP2020072675A (ja) 2020-05-14
RU2018102103A (ru) 2019-02-21
AU2020200624A9 (en) 2021-12-23
KR102285743B1 (ko) 2021-08-06
US20180282401A1 (en) 2018-10-04
ME03008B (me) 2018-10-20
WO2013041962A1 (en) 2013-03-28
AU2012311234A1 (en) 2014-05-01
SG10201912964PA (en) 2020-02-27
AU2020200624B2 (en) 2021-12-23
CL2014000679A1 (es) 2014-11-21
US20220010004A1 (en) 2022-01-13
RU2645259C2 (ru) 2018-02-19
DK2758433T3 (en) 2018-01-15
EP3275461A1 (en) 2018-01-31
HK1199459A1 (en) 2015-07-03
US9828421B2 (en) 2017-11-28
JP2022031631A (ja) 2022-02-22
KR20200084362A (ko) 2020-07-10
PL2758433T3 (pl) 2018-06-29
UA123390C2 (uk) 2021-03-31
JP7182316B2 (ja) 2022-12-02
SG10201912955PA (en) 2020-02-27
JP2018117631A (ja) 2018-08-02
JP6253583B2 (ja) 2017-12-27
US12404322B2 (en) 2025-09-02
CY1119792T1 (el) 2018-06-27
SG10201703771WA (en) 2017-06-29
JP2017093470A (ja) 2017-06-01
PT2758433T (pt) 2018-01-19
IL274440A (en) 2020-06-30
KR20210099167A (ko) 2021-08-11
KR20140063853A (ko) 2014-05-27
CN104185640A (zh) 2014-12-03
US11098106B2 (en) 2021-08-24
TR201800669T4 (tr) 2018-03-21
CL2015001314A1 (es) 2015-09-21
AU2012311234B2 (en) 2017-09-28
ES2656442T3 (es) 2018-02-27
IL231201B (en) 2018-06-28
US20170260263A1 (en) 2017-09-14
HRP20180083T1 (hr) 2018-02-23
HUE036177T2 (hu) 2018-06-28
US9845352B2 (en) 2017-12-19
SG11201400125RA (en) 2014-03-28
MY183989A (en) 2021-03-17
KR102130439B1 (ko) 2020-07-07
JP2014530597A (ja) 2014-11-20
US20150050215A1 (en) 2015-02-19
RU2014115481A (ru) 2015-10-27
BR112014006376A2 (pt) 2017-06-13
JP2018183160A (ja) 2018-11-22
UA115657C2 (uk) 2017-12-11
MX2014003357A (es) 2015-03-20
MX347505B (es) 2017-04-28
SI2758433T1 (en) 2018-02-28
EP2758433B1 (en) 2017-10-18
IL287794A (en) 2022-01-01
CN109265543A (zh) 2019-01-25
LT2758433T (lt) 2018-02-12
IL274440B (en) 2021-12-01
IL231201A0 (en) 2014-04-30
BR112014006376B1 (pt) 2021-07-27
RU2018102103A3 (enExample) 2021-05-31
RS56852B1 (sr) 2018-04-30
AU2017272259A1 (en) 2018-01-04
IL259775A (en) 2018-07-31
AU2017272259B2 (en) 2019-11-14
EP2758433A1 (en) 2014-07-30
AU2020200624A1 (en) 2020-02-20
SMT201800109T1 (it) 2018-05-02
JP6286590B2 (ja) 2018-02-28
CA2848346A1 (en) 2013-03-28
HRP20180083T8 (hr) 2018-07-27
CN115417916B (zh) 2025-12-30
ZA201401333B (en) 2015-09-30
US20170145082A1 (en) 2017-05-25
CN104185640B (zh) 2018-07-20

Similar Documents

Publication Publication Date Title
MX391157B (es) Terapia basada en proteina y diagnostico de patologia mediada por tau en la enfermedad de alzheimer.
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MX356800B (es) Anticuerpo tau humanizado.
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
WO2010115843A3 (en) Pharmaceutical composition
MX2019008758A (es) Anticuerpos anti-cd37 y usos de los mismos.
WO2019186276A8 (en) Antibody-based methods of detecting and treating alzheimer's disease
WO2014031694A3 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
GEP20125385B (en) Antibodies directed against amyloid-beta peptide and methods using same
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof
CY1123926T1 (el) Αντισωματα κατα της τρανσγλουταμινασης 2
WO2014007982A3 (en) C-terminal and central epitope a-beta antibodies
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
EA201300130A1 (ru) Способ лечения болезни альцгеймера
WO2014053110A3 (de) Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies
WO2009120659A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents
TH135133A (th) แอนติบอดีที่ต้าน il-17f ชนิดต่างๆ และวิธีการต่างๆ ในการใช้แอนติบอดีดังกล่าว
TH95385B (th) แอนติบอดีที่ได้รับการฮิวมาไนซ์
WO2009120657A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents
TH149802A (th) โปรตีนจับเกาะแอนติเจน